Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Exe6.0
Exenatide – Forschung
Überwiegend Mechanismus / Beobachtung
106 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Exenatide sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2004–2026 mit einer typischen Studiengröße von 464 Teilnehmenden.
Basierend auf 106 Studien · 21 Meta-Analysen · 76 RCTs · 77,347 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Blood sugar & glycemic controlKonsistente HbA1c-Senkungen (~0,8 % bei zweimal täglicher Gabe, ~1,3-1,9 % bei einmal wöchentlicher Gabe) über die Phase-3-Programme AMIGO und DURATION · Wochen bis Monate
Überwiegend Mechanismus / Beobachtung64 Studien
Weight managementDosisabhängige Gewichtsreduktion (typischerweise ~1,5-3 kg) statt Gewichtszunahme · Monate
Überwiegend Mechanismus / Beobachtung24 Studien
Safety & adverse effects
Überwiegend Mechanismus / Beobachtung19 Studien
Cardiovascular outcomes
Überwiegend Mechanismus / Beobachtung18 Studien
Aktives Forschungsgebiet
49 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
200420152026
1Meta-Analyse2019
Bonora BM, Avogaro A, Fadini GP · Acta Diabetol (2019)
Einfach gesagt: A primary composite outcome event occurred in 839 of 7356 patients (11.4%) in the exenatide group and in 905 of 7396 patients (12.2%) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00)... was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority).
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. · N Engl J Med (2017)
Large cardiovascular-outcomes RCT: 14,752 patients with type 2 diabetes (73.1% with prior cardiovascular disease), once-weekly exenatide 2 mg vs placebo added to usual care, median 3.2 years
Primary MACE composite NEUTRAL: HR 0.91 (95% CI 0.83-1.00); non-inferior for safety but NOT superior for efficacy (P=0.06 for superiority)
No significant difference in CV death, MI, stroke, heart-failure hospitalization, pancreatitis, pancreatic cancer, or medullary thyroid carcinoma
Einfach gesagt: GLP-1 and dual GIP/GLP-1 receptor agonists produced the greatest FM reduction but also decreased lean mass.
Rakhsha SS et al. · Diabetes, obesity & metabolism (2026)
For FM among Glucagon-like peptide-1 (GLP-1) and dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, tirzepatide showed the greatest reduction compared with placebo (MD -10.70 kg; 95% CI: -13.42 to -7.99), followed by liraglutide plus exercise.
For LBM, tirzepatide (MD -4.40 kg; 95% CI: -7.58 to -1.22) and liraglutide (MD -1.54 kg; 95% CI: -2.55 to -0.52) were associated with significant reductions.
GLP-1 and dual GIP/GLP-1 receptor agonists produced the greatest FM reduction but also decreased lean mass.
Einfach gesagt: Variability in urinary albumin-to-creatinine ratio estimates appears to reflect duration and baseline risk more than a lack of effect.
Huang R et al. · The Journal of international medical research (2026)
Primary outcomes were change in body weight (kg) and percentage change in urinary albumin-to-creatinine ratio; change in estimated glomerular filtration rate was the secondary outcome.
Glucagon-like peptide-1 receptor agonists reduced body weight (mean difference, -5.85 kg; 95% confidence interval: -7.78 to -3.92) with a consistent direction of effect across studies despite heterogeneity.
Glucagon-like peptide-1 receptor agonists lowered urinary albumin-to-creatinine ratio overall (mean difference, -27.94%; 95% confidence interval: -37.72 to -18.15).
Einfach gesagt: Overall, GLP-1 RAs improve weight and reduce insulin requirements in T1DM, potentially mitigating indirect CV risk factors; however their direct cardiovascular benefits remain unproven in the absence of dedicated outcome trials.
Wójcik-Sosnowska E et al. · International journal of molecular sciences (2026)
HbA1c reductions were statistically significant but modest (0.2-0.3%), with no improvement in Time in Range.
Secondary benefits included lower systolic blood pressure.
Safety data were mixed: the risk of severe hypoglycemia was not increased, whereas Time Below Range and gastrointestinal adverse events were more frequent.
Einfach gesagt: Further research is needed for normal-weight patients with prediabetes, for semaglutide's post-intervention effect, and for liraglutide in men.
Tsironikos GI, Tsolaki V, Zakynthinos G, Rammou V, Kyprianidou D, Antonogiannis T, Zakynthinos E, Bargiota A. · Diabetes/metabolism research and reviews (2026)
GLP-1 RAs restored normoglycemia compared to placebo (OR 4.62, 95% CI 2.85, 7.49; p-value < 0.00001).
Both semaglutide (OR 4.87, 95% CI 2.61, 9.09; p-value < 0.00001) and liraglutide (OR 5.43, 95% CI 1.34, 22.04; p-value 0.02) were effective but not exenatide.
Heterogeneity was large (Q 84.42, p-value < 0.00001; I 2 92%, 95% CI 77, 97%), attributed to the countries' performance and post-intervention follow-up in semaglutide-based RCTs and any subgroup analysis in liraglutide-based RCTs.
Einfach gesagt: GLP-1RAs are generally acceptable and tolerated in this population.
Srisurapanont M, Suttajit S, Likhitsathian S, Suradom C, Maneeton B. · International journal of psychiatry in medicine (2026)
Compared with placebo/usual care, GLP- 1RAs significantly reduced weight (MD = 6.17 kg, 95% CI=9.10 to_3.25, I 2 = 91.8%, 9 trials) and HbA1c (MD = 0.31%, 95% CI: 0.40 to 0.22, I 2 = 51.3%, 8 trials).
All-cause dropouts did not differ significantly between groups (RR = 0.98, 95% CI: 0.71 to 1.35, I 2 = 28.5%, 10 trials), nor did adverse effect dropouts (RR = 0.99, 95% CI: 0.35 to 2.77, I 2 = 31.6%, 5 trials).
Low certainty evidence supports the tolerability and efficacy of GLP-1RAs for weight and HbA1c reduction.